免疫测量的全球市场 - 趋势，技术，成长的机会(2025年)

最新报告 "全球免疫测定市场 - 趋势、技术、成长机会 (2025)" 对免疫测定进行了详细分析，免疫测定是体外诊断 (IVD) 行业最重要的细分领域之一，并提供了 2024 年至 2029 年的市场估值和预测。免疫测定是透过抗体-抗原交互作用检测目标分析物的诊断测试，是临床实验室和即时诊断 (POC) 环境中的基本工具，可用于检测蛋白质、荷尔蒙、药物和传染源。

随着自动化、微型化、多路復用和生物标记发现方面的进步，全球免疫测定市场持续扩张。儘管免疫测定是一项成熟的技术，但它仍在快速发展，以满足从中心实验室到自我检测应用的现代医疗保健需求。

市场区隔

按设定

• 中央实验室为基础的免疫测量法:
  • 用于核心实验室的诊断、监测和筛检。
  • 市场收入：主要贡献：传染病、心臟标记、肿瘤标记等。
  • 主要细分市场
    • 传染病标记物
    • 心臟标记
    • 代谢性疾病和激素
    • 肿瘤标记
    • 自体免疫和过敏检测
• 照护现场(POC)免疫测量:
  • 包括医院、诊所、零售店和自我检测中的横向流动和其他快速检测。
  • 易用性和分散式存取推动快速成长
  • 主要目标区隔市场
    • 传染病
    • 荷尔蒙/不孕不育
    • 心臟标记
    • 肿瘤学和粪便潜血试验 (FOBT)
    • 毒理学

依疾病类别细分

• 传染病：包括爱滋病毒、肝炎、抗甲氧西林金黄色葡萄球菌 (MRSA)、性传染病 (STD)、新冠肺炎 (COVID-19)、TORCH 等检测。
• 心臟标记：心臟衰竭和急诊护理检测成长强劲。
• 荷尔蒙和不孕症：实验室和即时检验 (POC) 的使用率均较高。
• 肿瘤/肿瘤标记：以实验室检测为主，其中以PSA、CEA、CA-125、AFP最为常见。
• 毒理学和药物监测：用于疼痛管理、急诊医学和药物滥用计画。
• 自体免疫和过敏：针对全身性疾病的新标靶和扩展的检测组。
• 基因组检测：包括产前筛检和利用免疫分析平台进行基因表现谱分析。
• 其他新兴领域：阿兹海默症、胃肠道疾病、移植医学、女性健康（例如子痫前症）。

地区趋势分析

• 新兴国家市场:
  • 北美和西欧，根据高度的医疗保健·基础设施和先进性的诊断法的引进占据着优势。
  • 先进亚太地区也完成了重要角色。
• 新兴市场:
  • 因为在南美，东欧，东南亚，非洲，集中型诊断被限定，免疫测量成为存取(点阅)扩大的关键。
  • 在资源的有限的环境，侧流和自我检验成为重要的工具。

研究方法与范围

本报告以美元为单位，介绍了2024-2029年期间全球免疫测定市场的情况。该报告分析了广泛的免疫测定技术，从高通量实验室仪器到手动即时诊断 (POC) 检测，包括快速免疫层析法和横流法。

虽然主要关注已开发地区（北美、西欧和亚太地区），但报告也认识到即时诊断在扩大医疗资源匮乏地区诊断可及性方面的重要性。

市场数据反映的是製造商的收入，而非零售价格或报销金额。由于设备成本通常包含在每次检测的定价中，因此细分市场的价值通常与检测量一致。

本报告中的研究结果结合了原始研究和二手资料。二手资料来源包括上市公司和专有资料库、行业报告、监管备案文件、公司出版物和同行评审期刊。这些资料提供了背景资讯、竞争力评估和策略见解。

为了验证和深化研究，Kalorama 对行业专家进行了30次访谈，其中包括高阶主管、产品和行销负责人、顾问、医疗保健专业人士以及政府代表。这些访谈提供了有关市场动态和趋势的定性见解。

对公司进行的额外联繫提供了有关收入、市场占有率和产品性能的确切数据。所有数据均与多个来源进行了交叉引用，并在可能的情况下透过公开资讯、专有见解和专家回馈进行了验证。

市场规模和预测以 2024 年为基准年，并结合历史趋势、人口变化、技术进步和全球市场扩张对 2029 年的预测。竞争格局分析反映了 2024 年及以后的格局。

目录

第1章 摘要整理

第2章 简介

• 免疫测量的历史和未来
• 免疫测量技术持续进化

第3章 科技，趋势，革新

• 概要- 免疫测量
  • 化学冷光免疫测量(CLIA)
  • 酵素免疫测量(ELISA)
  • 萤光免疫测量(FIA)
  • 免疫组织化学(IHC)
  • 侧流免疫测量(LFIA)
  • 无线电免疫测量(RIA)
  • 西方印渍术
• 免疫测量技术的创新和新的趋势
• 概要- 计量仪器平台
  • 微孔板免疫分析与自动化
  • 免疫分析自动化
  • 平台创新：小型化、微流体技术、多重化
  • 即时检验 (POC) 和小型设备
  • 晶片实验室 (LOC) 和生物晶片
  • 范例：Veravas VeraBIND 技术
• 样品的种类
  • 血
  • 尿
  • 唾液

第4章 不同设定市场区隔

• 中央研究所
• 迅速·就地检验

第5章 免疫测量诊断市场各用途趋势

• 过敏
• 自体免疫疾病
• 心臟标记
• 遗传基因检验
• 感染疾病
• 实验室为基础的感染疾病免疫测量
  • 血液检测
  • 肝炎
  • 莱姆病
  • 快速和即时检测
  • 逆转录病毒
  • 性传染病
  • TORCH
  • 新冠肺炎 (COVID-19)
  • 其他传染病
• 代谢障碍及其他荷尔蒙
  • 妊娠·生殖荷尔蒙
  • 甲状腺
• 肿瘤学- 肿瘤标记（癌症筛检）
  • 实验室为基础的肿瘤免疫测量
• 毒物学
  • 滥用药物
  • 治疗药物监测
• 免疫测量疾病市场上及其他的疾病类别

第6章 免疫测量的市场机会与课题

• 免疫测量市场- 概要
• 免疫测量市场的推动要素与课题
  • 促进因素
• 免疫测量法的创新的新领域
  • 肠胃障碍
  • 移植管理
  • 妊娠中毒症
  • 阿兹海默症
• 新兴国际市场
• 实验室开发试验
• 人员不足
• 免疫测量今后的预测

第7章 免疫测量市场分析

• 市场概要与市场区隔
• 竞争分析
• 各地区免疫测量市场
  • 北美
  • 欧洲
  • 亚太地区
  • 其他的国家

第8章 企业简介

• 1 Step Detect Associates, LLC
• Abbott Laboratories
• Abingdon Health, Ltd.
• Access Bio, Inc
• AccuBioTech Co, Ltd.
• ACON Laboratories, Inc
• AESKU. DIAGNOSTICS
• Aidian Oy
• Alfa Scientific Designs, Inc
• American Laboratory Products Company (ALPCO)
• Anbio Biotechnology
• ARKRAY, Inc
• Arlington Scientific, Inc.
• Artron Laboratories Inc.
• Associates of Cape Cod, Inc. (ACC)
• Autobio Diagnostics Co., Ltd
• Avioq, Inc
• Awareness Technology
• Beckman Coulter, Inc
• Becton Dickinson (BD)
• Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
• Bhat Bio-Tech India Private Ltd. (BBI)
• BioCheck, Inc.
• Biohit Oyj (Biohit Healthcare)
• bioLytical Laboratories
• BioMedomics, Inc.
• Biomerica
• bioMerieux SA
• BioPorto Diagnostics
• Bio-Rad Laboratories Inc.
• Bioscience (Tianjin) Diagnostic Technology Co., Ltd.
• Bio-Techne
• Biotron Diagnostics, Inc.
• Boditech Med Inc.
• Boson Biotech Co. Ltd
• BUHLMANN Laboratories AG
• Certest Biotec
• Chembio Diagnostic Systems, Inc.
• Clarity Diagnostics, LLC
• Confirm Biosciences
• CTK Biotech, Inc.
• Diagenics Group SE
• DIALAB GmbH
• Diametra
• DiaSorin S.p.A.
• DiaSource ImmunoAssays SA
• DiaSys Diagnostic Systems GmbH (Mindray)
• Diazyme Laboratories, Inc.
• Dr. Fooke-Achterrath Laboratorien GmbH
• Eiken Chemical Co Ltd.
• EKF Diagnostics Holdings plc
• ELITechGroup S.A.S.
• Eurobio Scientific
• Eurospital Spa
• EY Laboratories
• Fujirebio-US, Inc.
• GenBio
• Gold Standard Diagnostics
• Grifols International S.A.
• Hemosure, Inc.
• HYCOR Biomedical, Inc.
• Immuno-Mycologics, Inc.
• Immunosciences Lab, Inc.
• Immunostics, Inc
• InBios International, Inc.
• JAL Innovation PTE LTD
• Jant Pharmacal Corporation
• J Mitra & Co., Pvt. Ltd.
• KRONUS
• Kypha
• Labsystems Diagnostics Oy
• LamdaGen Corporation
• LifeSign, LLC
• Macherey-Nagel GmbH & Co. KG
• Medix Biochemica
• MedMira, Inc
• Mercodia AB
• Meridian BioScience, Inc
• Monobind, Inc
• Nano-Ditech Corporation
• Nexus Dx Inc
• Nova Biomedical, Corp.
• Oasis Diagnostics Corporation
• Operon
• OPKO Health, Inc
• OraSure Technologies, Inc.
• PixCell Medical Technologies
• Polymedco, Inc
• Precision Biosensor
• Preventis GmbH
• Princeton Biomeditech Corporation
• PTS Diagnostics
• Qualigen, Inc.
• Quanterix Corporation
• QuidelOrtho Corporation
• Radiometer Medical A/S
• Response Biomedical Corp.
• Reszon Diagnostics International Sdn. Bhd.
• Revvity
• Roche Diagnostic Corporation
• Savyon Diagnostics Ltd.
• Sekisui Diagnostics LLC
• Siemens Healthineers
• Syntron Bioresearch, Inc.
• Sysmex Corporation
• TECHLAB, Inc.
• Teco Diagnostics
• Thermo Fisher Scientific, Inc
• Tosoh Bioscience, Inc.
• Trinity Biotech PLC
• True Diagnostics
• VedaLab
• Vircell
• WAMA Diagnostica
• Werfen Group
• Zeus Scientific, Inc

Kalorama Information's new report, "Global Immunoassay Market: Trends, Technologies, and Growth Opportunities, 2025", provides an in-depth analysis of one of the most pivotal segments of the in vitro diagnostics (IVD) industry with market estimates and forecasts spanning 2024-2029. Immunoassays-diagnostic tests that detect target analytes via antibody-antigen interactions-are foundational tools in clinical laboratories and point-of-care (POC) settings, enabling the detection of proteins, hormones, drugs, and infectious agents.

The global immunoassay market continues to expand, driven by advances in automation, miniaturization, multiplexing, and biomarker discovery. Despite being a mature technology, immunoassays are evolving rapidly to meet modern healthcare needs-from central labs to self-testing applications.

Market Segmentation

By Setting

• Centralized Lab-Based Immunoassays:
  • Used in core labs for diagnostics, monitoring, and screening.
  • Market Sales: Major contributors include infectious diseases, cardiac markers, and tumor markers.
  • Top segments covered:
    • Infectious Disease
    • Cardiac Markers
    • Metabolic Disorders & Hormones
    • Tumor Markers
    • Autoimmune & Allergy Testing
• Point-of-Care (POC) Immunoassays:
  • Includes lateral flow and other rapid tests in hospitals, clinics, retail settings, and self-testing.
  • Rapidly growing due to ease of use and decentralized access.
  • Top segments covered:
    • Infectious Disease
    • Hormone/Fertility
    • Cardiac Markers
    • Oncology & FOBT
    • Toxicology

Breakout By Disease Category

• Infectious Disease: Largest and most diverse segment; includes tests for HIV, hepatitis, MRSA, STDs, COVID-19, and TORCH.
• Cardiac Markers: Strong growth from heart failure and acute care testing.
• Hormones & Fertility: High usage in both labs and POC; includes reproductive and thyroid hormones.
• Oncology/Tumor Markers: Focus on PSA, CEA, CA-125, AFP with lab-based dominance.
• Toxicology & Drug Monitoring: Used in pain management, emergency medicine, and substance abuse programs.
• Autoimmune & Allergy: Emerging targets and expanded panels for systemic diseases.
• Genetic Testing: Includes prenatal screening and gene expression profiling via immunoassay platforms.
• Other Emerging Areas: Alzheimer's disease, gastrointestinal disorders, transplant medicine, and women's health (e.g., preeclampsia).

Analysis of Geographic Trends

• Developed Markets:
  • North America and Western Europe dominate due to high healthcare infrastructure and adoption of advanced diagnostics.
  • Developed Asia Pacific also plays a key role.
• Emerging Markets:
  • Immunoassays are key to expanding access in Latin America, Eastern Europe, Southeast Asia, and Africa, where centralized diagnostics are limited.
  • Lateral flow and self-testing are critical tools in resource-limited settings.

Scope and Methodology

This report presents the global immunoassay market in U.S. dollars, covering the years 2024 through 2029. It analyzes a wide range of immunoassay technologies, from high-throughput lab instruments to manual point-of-care (POC) tests, including rapid immunochromatographic or lateral flow formats.

The primary focus is on developed regions-North America, Western Europe, and developed Asia-Pacific-while also recognizing the importance of POC testing in expanding diagnostic access in underserved areas.

Market data reflects manufacturer revenue rather than retail prices or reimbursements. Segment values generally align with test volumes, as instrument costs are often bundled into per-test pricing.

A blend of primary and secondary research underpins the report's findings. Secondary sources included public and proprietary databases, industry reports, regulatory filings, company publications, and peer-reviewed journals. These sources provided context, competitor identification, and strategic insights.

To validate and deepen the research, Kalorama conducted over 30 interviews with industry experts such as executives, product and marketing leaders, consultants, healthcare professionals, and government representatives. These interviews provided qualitative insights into market dynamics and trends.

Additional outreach to companies yielded specific figures on revenue, market share, and product performance. All data were verified against multiple sources and, when possible, triangulated using public disclosures, proprietary insights, and expert feedback.

Market sizing and forecasts are based on 2024 as the base year, with projections through 2029 supported by historical trends, demographic shifts, technological advances, and global market expansion. Competitive analysis reflects the landscape in 2024, with forward-looking trends identified for subsequent years.

Table of Contents

Chapter 1: Executive Summary

• Overview
• Scope and Methodology
• Market Overview
  • Table 1-1: Global Immunoassay Market, 2024-2029 ($ million) [Lab-based, POC-based]
  • Figure 1-1: Global Immunoassay Market, 2024-2029 ($ million) [Lab-based, POC-based]
  • Figure 1-2: Global Immunoassay Market Share, 2024-2029 ($ million) [Lab-based, POC-based]
• Competitive Summary

Chapter 2: Introduction

• History and Future of Immunoassays
• Immunoassay Technology Continues to Evolve

Chapter 3: Technology, Trends, and Innovations

• Overview - Immunoassays
  • Table 3-1: Immunoassay Sensitivity, by Technology Type and Setting (Lab, POC) [CLIA, ELISA, FIA, IHC, LFIA, RIA]
  • Chemiluminescent Immunoassay (CLIA)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Fluoroimmunoassay (FIA)
  • Immunohistochemistry (IHC)
  • Lateral Flow Immunoassay (LFIA)
  • Radioimmunoassay (RIA)
  • Western Blotting
• Immunoassay Technology Innovations and Emerging Trends
• Overview - Instrument Platforms
  • Microtiter Plate-Based Immunoassays and Automation
  • Automation in Immunoassays
  • Platform Innovations: Miniaturization, Microfluidics, and Multiplexing
  • Point-of-Care (POC) and Miniaturized Devices
  • Lab-on-a-Chip (LOC) and Biochips
  • Case Example: Veravas VeraBIND Technology
    • Table 3-2: Selected Immunoassay Technologies
• Specimen Types
  • Blood
  • Urine
  • Saliva
    • Table 3-3: Selected Companies with Saliva or Oral-Fluid Collection Devices

Chapter 4: Market Segment by Setting

• Centralized Laboratories
  • Table 4-1: Global Lab-based Immunoassay Market, by Application Segment, 2024 ($ million) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Others]
  • Figure 4-1: Global Lab-based Immunoassay Market, by Application Segment, 2024 ($ million) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Others]
  • Figure 4-2: Global Lab-based Immunoassay Market Distribution, by Application Segment, 2024 (%) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Others]
  • Companies Marketing to Centralized Laboratories
    • Table 4-2: Selected Companies Marketing Central Lab-Based Immunoassays Worldwide
• Rapid and Point-of-Care Testing
  • Table 4-3: Global POC-based Immunoassay Market, by Application Segment, 2024 ($ million) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other]
  • Figure 4-3: Global POC-based Immunoassay Market, by Application Segment, 2024 ($ million) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other]
  • Figure 4-4: Global POC-based Immunoassay Market Distribution, by Application, 2024 (%) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology, Toxicology, Other]
  • POC Testing in Hospitals
  • Physician's Office Laboratories and Clinics
  • Retail Clinics
  • Other Professional POC Testing
  • Self-Testing
  • Companies Marketing Immunoassay for POC Testing
    • Table 4-4: Selected Companies Marketing Immunoassay and/or Lateral Flow Tests for POC Worldwide

Chapter 5: Immunoassay Diagnostic Market Activity by Application

• Table 5-1: Immunoassay Market Disease Categories
• Allergy
  • Figure 5-1: Global Allergy Immunoassay Market, 2024-2029 ($ million)
  • Table 5-2: Selected Companies Marketing Immunoassays for Allergy Diagnostics
• Autoimmune Disease
  • Figure 5-2: Global Autoimmune Disease Immunoassay Market, 2024-2029 ($ million)
  • Table 5-3: Selected Autoantibodies Detected by Autoimmune Immunoassays
• Cardiac Markers
  • Figure 5-3: Global Cardiac Marker Immunoassay Market, 2024-2029 ($ million)
  • Table 5-4: Selected Cardiac Marker Immunoassays
  • Table 5-5: Selected Cardiac Marker Innovations
• Genetic Testing
  • Figure 5-4: Global Genetic Immunoassay Market, 2024-2029 ($ million)
• Infectious Disease
  • Figure 5-5: Global Infectious Disease Immunoassay Market, 2024-2029 ($ million)
• Lab-based Infectious Disease Immunoassays
  • Table 5-6: Global Lab-based Infectious Disease Immunoassay Sales, 2024 ($ million) [Blood banking, C. diff, Hepatitis, HIV, MRSA, Respiratory, STD, Staphylococci, TORCH, Other infectious diseases]
  • Figure 5-6: Global Lab-based Infectious Disease Immunoassay Sales, 2024 ($ million) [Blood banking, C. diff, Hepatitis, HIV, MRSA, Respiratory, STD, Staphylococci, TORCH, Other infectious diseases]
  • Figure 5-7: Global Lab-based Infectious Disease Immunoassay Market Share, 2024 (%) [Blood banking, C. diff, Hepatitis, HIV, MRSA, Respiratory, STD, Staphylococci, TORCH, Other infectious diseases]
  • Blood Screening
    • Table 5-7: Selected Infectious Disease Immunoassays
    • Table 5-8: Selected Companies Marketing Immunoassays for Infectious Disease
  • Hepatitis
  • Lyme Disease
  • Rapid and POC Testing
  • Retroviral
  • Sexually Transmitted Diseases
  • ToRCH
  • COVID-19
    • Table 5-9: Selected Antigen POC and Home Immunoassay Tests for SARS-CoV-2
  • Other Infectious Diseases
• Metabolic Disorders and Other Hormones
  • Figure 5-8: Global Metabolic and Hormone Disorder Immunoassay Market, 2024-2029 ($ million)
  • Table 5-10: Selected Metabolic and Other Hormone Immunoassays
  • Fertility/Pregnancy/Reproductive Hormones
    • Table 5-11: Selected Fertility and Reproductive Hormone Immunoassays
  • Thyroid
    • Table 5-12: Selected Thyroid Hormone Immunoassays
• Oncology - Tumor Markers
  • Figure 5-9: Global Oncology Immunoassay Market, 2024-2029 ($ million)
  • Lab-based Oncology Immunoassays
    • Table 5-13: Global Lab-based Tumor Marker Immunoassay Sales, 2024 ($ million) [AFP, CA-125, CEA, PSA, Others]
    • Figure 5-10: Global Lab-based Tumor Marker Immunoassay Sales, 2024 ($ million) [AFP, CA-125, CEA, PSA, Others]
    • Figure 5-11: Global Lab-based Tumor Marker Immunoassay Market Share, 2024 (%) [AFP, CA-125, CEA, PSA, Others]
    • Table 5-14: Selected Companies Marketing Immunoassays for Tumor Markers
    • Table 5-15: Selected Companies Marketing Metabolic Immunoassays
• Toxicology
  • Figure 5-12: Global Toxicology Marker Immunoassay Market, 2024-2029 ($ million)
  • Drugs of Abuse
    • Table 5-16: Selected Drugs of Abuse Immunoassays
  • Therapeutic Drug Monitoring
    • Table 5-17: Selected Therapeutic Drug Monitoring Immunoassays
• Other Disease Categories in Immunoassay Disease Market
  • Figure 5-13: Other Immunoassay Market, 2024-2029 ($ million)
  • Table 5-18: Selected Other Immunoassays

Chapter 6: Market Opportunities and Issues for Immunoassays

• Immunoassay Market - Overview
• Immunoassay Market Drivers and Challenges
  • Drivers
• New and Emerging Areas of Immunoassay Innovation
  • Gastrointestinal Disorders
    • Table 6-1: Selected Inflammatory Bowel Disease Test Innovations
  • Transplant Management
    • Table 6-2: Selected Immunoassays for Transplant Medicine
  • Preeclampsia
    • Table 6-3: Selected Women's Health Innovations
  • Alzheimer's Disease
    • Table 6-4: Selected Innovations for Alzheimer's Disease Immunoassays
    • Table 6-5: Selected Immunoassay Innovations
• Emerging International Markets
  • Table 6-6: Selected Companies Outside of North America, Europe, or Japan Marketing Immunoassays
• Lab-Developed Tests
• Staffing Shortages
• Outlook for Immunoassays

Chapter 7: Immunoassay Market Analysis

• Market Overview and Market Segments
  • Table 7-1: Global Immunoassay Market, by Laboratory Setting, 2024-2029 ($ million) [Lab-based, POC-based]
  • Figure 7-1: Global Immunoassay Market, by Laboratory Setting, 2024-2029 ($ million) [Lab-based, POC-based]
  • Figure 7-2: Global Immunoassay Market Segment Share, by Laboratory Setting, 2024 (%) [Lab-based, POC-based]
  • Central Lab-based Immunoassay Market
    • Table 7-2: Global Lab-based Immunoassay Market, by Application, 2024-2029 ($ million) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Other]
    • Figure 7-3: Global Lab-based Immunoassay Market, by Application, 2024-2029 ($ million) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Other]
  • Point of Care/Rapid Test Immunoassays by Disease Category
    • Table 7-3: Global POC Immunoassay Market Analysis, by Disease Category, 2024 ($ million) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other]
    • Figure 7-4: Global POC Immunoassay Market Analysis, by Disease Category, 2024 ($ million) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other]
    • Figure 7-5 Global POC Immunoassay Market Analysis, by Disease Category Market Share, 2024 (%) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other]
  • Immunoassay Market by Technology Type
    • Table 7-4: Global Immunoassay Market, by Technology Segment, 2024-2029 ($ million) [CLIA, ELISA, FIA, IHC, LFIA, RIA, Other]
    • Figure 7-6: Global Immunoassay Market, by Technology Segment, 2024-2029 ($ million) [CLIA, ELISA, FIA, IHC, LFIA, RIA, Other]
    • Table 7-5: Global Immunoassay Market Share, by Technology Segment, 2024 (%) [CLIA, ELISA, FIA, IHC, LFIA, RIA, Other]
    • Figure 7-7: Global Immunoassay Market Share, by Technology Segment, 2024 (%) [CLIA, ELISA, FIA, IHC, LFIA, RIA, Other]
• Competitive Analysis
  • Table 7-6: Global Immunoassay Market Analysis, by Competitor Revenues ($ million) and Market Share (%), 2024 [Abbott, Becton Dickinson, Bio-Rad, bioMerieux, Bruker - CALID, Danaher, DiaSorin, QuidelOrtho, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Others]
  • Figure 7-8: Global Immunoassay Market Analysis, by Competitor Revenues ($ million), 2024 [Abbott, Becton Dickinson, Bio-Rad, bioMerieux, Bruker - CALID, Danaher, DiaSorin, QuidelOrtho, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Others]
  • Figure 7-9: Global Immunoassay Market Analysis, by Competitor Market Share, 2024 (%) [Abbott, Becton Dickinson, Bio-Rad, bioMerieux, Bruker - CALID, Danaher, DiaSorin, QuidelOrtho, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Others]
• Immunoassay Market by Geographic Regions
  • Table 7-7: Immunoassay Market, by Geographic Region, 2024-2029 ($ million) [Asia Pacific, Europe, North America, Rest of World]
  • Figure 7-10: Immunoassay Market, by Geographic Region, 2024-2029 ($ million) [Asia Pacific, Europe, North America, Rest of World]
  • Figure 7-11: Immunoassay Market Share, by Geographic Region, 2024 (%) [Asia Pacific, Europe, North America, Rest of World]
  • North America
  • Europe
    • Table 7-8: Immunoassay Market, by European Geographic Region, 2024 ($ million) [France, Germany, Italy, Spain, United Kingdom, Others]
    • Figure 7-12: Immunoassay Market, by European Geographic Region, 2024 ($ million) [France, Germany, Italy, Spain, United Kingdom, Others]
    • Figure 7-13: Immunoassay Market Share, by European Geographic Region, 2024 (%) [France, Germany, Italy, Spain, United Kingdom, Others]
  • Asia Pacific
    • Table 7-9: Immunoassay Market, by Asia Pacific Geographic Region, 2024 ($ million) [China, India, Japan, Others]
    • Figure 7-14: Immunoassay Market, by Asia Pacific Geographic Region, 2024 ($ million) [China, India, Japan, Others]
    • Figure 7-15: Immunoassay Market Share, by Asia Pacific Geographic Region, 2024 (%) [China, India, Japan, Others]
  • Rest of World
    • Table 7-10: Immunoassay Market, by Rest of World Geographic Region, 2024 ($ million) [Brazil, Mexico, Saudi Arabia, South Africa, Turkey, Others]
    • Figure 7-16: Immunoassay Market, by Rest of World Geographic Region, 2024 ($ million) [Brazil, Mexico, Saudi Arabia, South Africa, Turkey, Others]
    • Figure 7-17: Immunoassay Market Share, by Rest of World Geographic Region, 2024 (%) [Brazil, Mexico, Saudi Arabia, South Africa, Turkey, Others]

Chapter 8: Company Profiles

• 1 Step Detect Associates, LLC
  • Table 8-1: 1-Step Detect Associates Corporate Summary
  • Company Overview
  • Products
• Abbott Laboratories
  • Table 8-2: Abbott Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-3: Abbott Revenues, 2023-2024 ($millions)
• Abingdon Health, Ltd.
  • Table 8-4: Abingdon Health Corporate Summary
  • Company Overview
  • Products
• Access Bio, Inc.
  • Table 8-5: Access Bio Summary
  • Company Overview
  • Products
• AccuBioTech Co, Ltd.
  • Table 8-6: AccuBioTech Corporate Summary
  • Company Overview
  • Products
• ACON Laboratories, Inc
  • Table 8-7: ACON Laboratories Corporate Summary
  • Company Overview
  • Products
• AESKU. DIAGNOSTICS
  • Table 8-8: AESKU.DIAGNOSTICS Corporate Summary
  • Company Overview
  • Products
• Aidian Oy
  • Table 8-9: Aidian Corporate Summary
  • Company Overview
  • Products
• Alfa Scientific Designs, Inc
  • Table 8-10: Alfa Scientific Design
  • Company Overview
  • Products
• American Laboratory Products Company (ALPCO)
  • Table 8-11: American Laboratory Products Corporate Summary
  • Company Overview
  • Products
• Anbio Biotechnology
  • Table 8-12: Anbio Biotechnology Corporate Summary
  • Company Overview
  • Products
• ARKRAY, Inc
  • Table 8-13: ARKRAY Corporate Summary
  • Company Overview
  • Products
• Arlington Scientific, Inc.
  • Table 8-14: Arlington Scientific Corporate Summary
  • Company Overview
  • Products
• Artron Laboratories Inc.
  • Table 8-15: Artron Laboratories Corporate Summary
  • Company Overview
  • Products
• Associates of Cape Cod, Inc. (ACC)
  • Table 8-16: Associates of Cape Cod Corporate Summary
  • Company Overview
  • Products
• Autobio Diagnostics Co., Ltd
  • Table 8-17: Autobio Diagnostics Corporate Summary
  • Company Overview
  • Products
• Avioq, Inc.
  • Table 8-18: Avioq Corporate Summary
  • Company Overview
  • Products
• Awareness Technology
  • Table 8-19: Awareness Technology Corporate Summary
  • Company Overview
  • Products
• Beckman Coulter, Inc
  • Table 8-20: Beckman Coulter Corporate Summary
  • Company Overview
  • Products
• Becton Dickinson (BD)
  • Table 8-21: BD Corporate Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-22: BD Corporation Revenue, 2023-2024 ($ million)
• Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
  • Table 8-23: Beijing Wantai Biological Pharmacy Enterprise Corporate Summary
  • Company Overview
  • Products
• Bhat Bio-Tech India Private Ltd. (BBI)
  • Table 8-24: Bhat Bio-Tech India Private Corporate Summary
  • Company Overview
  • Products
• BioCheck, Inc.
  • Table 8-25: BioCheck Corporate Summary
  • Company Overview
  • Products
• Biohit Oyj (Biohit Healthcare)
  • Table 8-26: Biohit Oyj Corporate Summary
  • Company Overview
  • Products
• bioLytical Laboratories
  • Table 8-27: bioLytical Laboratories Corporate Summary
  • Company Overview
  • Products
• BioMedomics, Inc.
  • Table 8-28: BioMedomics Corporate Summary
  • Company Overview
  • Products
• Biomerica
  • Table 8-29: Biomerica Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-30: Biomerica Corporation Revenue, 2023-2024 ($ million)
• bioMerieux SA
  • Table 8-31: bioMerieux SA Corporate Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-32: bioMerieux Revenues, 2023-2024 (Euro- millions)
• BioPorto Diagnostics
  • Table 8-33: BioPorto Diagnostics Corporate Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-34: BioPorto Diagnostics Revenues, 2023-2024 (DKK millions)
• Bio-Rad Laboratories Inc.
  • Table 8-35: Bio-Rad Labs Corporate Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-36: Bio-Rad Corporation Revenue, 2023-2024 ($ million)
• Bioscience (Tianjin) Diagnostic Technology Co., Ltd.
  • Table 8-37: Bioscience (Tianjin) Diagnostic Technology Corporate Summary
  • Company Overview
  • Products
• Bio-Techne
  • Table 8-38: Bio-Techne Corporate Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-39: Bio-Techne, 2023-2024 ($ million)
• Biotron Diagnostics, Inc.
  • Table 8-40: Biotron Diagnostics Corporate Summary
  • Company Overview
  • Products
• Boditech Med Inc.
  • Table 8-41: Boditech Med Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-42: Boditech Med Revenues 2023-2024 (KRW billion)
• Boson Biotech Co. Ltd
  • Table 8-43: Boson Biotech Corporate Summary
  • Company Overview
  • Products
• BUHLMANN Laboratories AG
  • Table 8-44: BUHLMANN Laboratories Summary
  • Company Overview
  • Products
• Certest Biotec
  • Table 8-45: Certest Biotec Summary
  • Company Overview
  • Products
• Chembio Diagnostic Systems, Inc.
  • Table 8-46: Chembio Diagnostic Corporate Summary
  • Company Overview
  • Products
• Clarity Diagnostics, LLC
  • Table 8-47: Clarity Diagnostics Corporate Summary
  • Company Overview
  • Products
• Confirm Biosciences
  • Table 8-48: Confirm Biosciences Corporate Summary
  • Company Overview
  • Products
• CTK Biotech, Inc.
  • Table 8-49: CTK Biotech Corporate Summary
  • Company Overview
  • Products
• Diagenics Group SE
  • Table 8-50: Diagenics Group Corporate Summary
  • Company Overview
  • Products
• DIALAB GmbH
  • Table 8-51: DIALAB Summary
  • Company Overview
  • Products
• Diametra
  • Table 8-52: Diametra Corporate Summary
  • Company Overview
  • Products
• DiaSorin S.p.A.
  • Table 8-53: DiaSorin Corporate Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-54: DiaSorin 2023-2024 (Euro- thousand)
• DiaSource ImmunoAssays SA
  • Table 8-55: DiaSource ImmunoAssays Corporate Summary
  • Company Overview
  • Products
• DiaSys Diagnostic Systems GmbH (Mindray)
  • Table 8-56: DiaSys Diagnostic Systems Corporate Summary
  • Company Overview
  • Products
• Diazyme Laboratories, Inc.
  • Table 8-57: Diazyme Laboratories Corporate Summary
  • Company Overview
  • Products
• Dr. Fooke-Achterrath Laboratorien GmbH
  • Table 8-58: Dr. Fooke-Achterrath Laboratorien Corporate Summary
  • Company Overview
  • Products
• Eiken Chemical Co Ltd.
  • Table 8-59: Eiken Chemical Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-60: Eiken Chemical Revenues, 2023-2024 (million yen)
• EKF Diagnostics Holdings plc
  • Table 8-61: EKF Diagnostics Corporate Summary
  • Company Overview
  • Products
• ELITechGroup S.A.S.
  • Table 8-62: ELITechGroup Corporate Summary
  • Company Overview
  • Products
• Eurobio Scientific
  • Table 8-63: Eurobio Scientific Corporate Summary
  • Company Overview
  • Products
• Eurospital Spa
  • Table 8-64: Eurospital Summary
  • Company Overview
  • Products
• EY Laboratories
  • Table 8-65: EY Laboratories Summary
  • Company Overview
  • Products
• Fujirebio-US, Inc.
  • Table 8-66: Fujirebio Corporate Summary
  • Company Overview
  • Products
• GenBio
  • Table 8-67: GenBio Corporate Summary
  • Company Overview
  • Products
• Gold Standard Diagnostics
  • Table 8-68: Gold Standard Diagnostics Corporate Summary
  • Company Overview
  • Products
• Grifols International S.A.
  • Table 8-69: Grifols International S.A. Corporate Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-70: Grifols Revenue, 2023-2024 (Euro- million)
• Hemosure, Inc.
  • Table 8-71: Hemosure Corporate Summary
  • Company Overview
  • Products
• HYCOR Biomedical, Inc.
  • Table 8-72: HYCOR Biomedical Corporate Summary
  • Company Overview
  • Products
• Immuno-Mycologics, Inc.
  • Table 8-73: Immuno-Mycologics Corporate Summary
  • Company Overview
  • Products
• Immunosciences Lab, Inc.
  • Table 8-74: Immunosciences Lab Corporate Summary
  • Company Overview
  • Products
• Immunostics, Inc
  • Table 8-75: Immunostics Corporate Summary
  • Company Overview
  • Products
• InBios International, Inc.
  • Table 8-76: InBios Corporate Summary
  • Company Overview
  • Products
• JAL Innovation PTE LTD
  • Table 8-77: JAL Innovation Corporate Summary
  • Company Overview
  • Products
• Jant Pharmacal Corporation
  • Table 8-78: Jant Pharmacal Summary
  • Company Overview
  • Products
• J Mitra & Co., Pvt. Ltd.
  • Table 8-79: J Mitra Corporate Summary
  • Company Overview
  • Products
• KRONUS
  • Table 8-80: KRONUS Corporate Summary
  • Company Overview
  • Products
• Kypha
  • Table 8-81: Kypha Corporate Summary
  • Company Overview
  • Products
• Labsystems Diagnostics Oy
  • Table 8-82: Labsystems Diagnostics Corporate Summary
  • Company Overview
  • Products
• LamdaGen Corporation
  • Table 8-83: LamdaGen Corporate Summary
  • Company Overview
  • Products
• LifeSign, LLC
  • Table 8-84: LifeSign Summary
  • Company Overview
  • Products
• Macherey-Nagel GmbH & Co. KG
  • Table 8-85: Macherey-Nagel Corporate Summary
  • Company Overview
  • Products
• Medix Biochemica
  • Table 8-86: Medix Biochemica Summary
  • Company Overview
  • Products
• MedMira, Inc
  • Table 8-87: MedMira Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-88: MedMira, Revenues 2023-2024 ($ thousands)
• Mercodia AB
  • Table 8-89: Mercodia AB Summary
  • Company Overview
  • Products
• Meridian BioScience, Inc
  • Table 8-90: Meridian BioScience Corporate Summary
  • Company Overview
  • Products
• Monobind, Inc
  • Table 8-91: Monobind Corporate Summary
  • Company Overview
  • Products
• Nano-Ditech Corporation
  • Table 8-92: Nano-Ditech Corporate Summary
  • Company Overview
  • Products
• Nexus Dx Inc
  • Table 8-93: Nexus Dx Corporate Summary
  • Company Overview
  • Products
• Nova Biomedical, Corp.
  • Table 8-94: Nova Biomedical Corporate Summary
  • Company Overview
  • Products
• Oasis Diagnostics Corporation
  • Table 8-95: Oasis Diagnostics Corporate Summary
  • Company Overview
  • Products
• Operon
  • Table 8-96: Operon Corporate Summary
  • Company Overview
  • Products
• OPKO Health, Inc
  • Table 8-97: OPKO Health Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-98: OPKO Health Revenues, 2023-2024 ($ million)
• OraSure Technologies, Inc.
  • Table 8-99: OraSure Technologies Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-100: OraSure Revenues, 2023-2024 ($ million)
• PixCell Medical Technologies
  • Table 8-101: PixCell Corporate Summary
  • Company Overview
  • Products
• Polymedco, Inc
  • Table 8-102: Polymedco Corporate Summary
  • Company Overview
  • Products
• Precision Biosensor
  • Table 8-103: Precision Biosensor Corporate Summary
  • Company Overview
  • Products
• Preventis GmbH
  • Table 8-104: Preventis Corporate Summary
  • Company Overview
  • Products
• Princeton Biomeditech Corporation
  • Table 8-105: Princeton Biomeditech Corporate Summary
  • Company Overview
  • Products
• PTS Diagnostics
  • Table 8-106: PTS Corporate Summary
  • Company Overview
  • Products
• Qualigen, Inc.
  • Table 8-107: Qualigen Corporate Summary
  • Company Overview
  • Products
• Quanterix Corporation
  • Table 8-108: Quanterix Corporate Summary
  • Company Overview
  • Products
• QuidelOrtho Corporation
  • Table 8-109: QuidelOrtho Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-110: QuidelOrtho Revenues, 2023-2024 ($ million)
• Radiometer Medical A/S
  • Table 8-111: Radiometer Medical Corporate Summary
  • Company Overview
  • Products
• Response Biomedical Corp.
  • Table 8-112: Response Biomedical Corporate Summary
  • Company Overview
  • Products
• Reszon Diagnostics International Sdn. Bhd.
  • Table 8-113: Reszon Diagnostics Corporate Summary
  • Company Overview
  • Products
• Revvity
  • Table 8-114: Revvity Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-115: Revvity Revenues, 2023-2024 ($ million)
• Roche Diagnostic Corporation
  • Table 8-116: Roche Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-117: Roche Diagnostics Revenue, 2023-2024 (CHF millions)
• Savyon Diagnostics Ltd.
  • Table 8-118: Savyon Diagnostics Summary
  • Company Overview
  • Products
• Sekisui Diagnostics LLC
  • Table 8-119: Sekisui Diagnostics Corporate Summary
  • Company Overview
  • Products
• Siemens Healthineers
  • Table 8-120: Siemens Healthineers Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-121: Siemens Healthineers Revenue, 2023-2024 (Euro- millions)
• Syntron Bioresearch, Inc.
  • Table 8-122: Syntron Bioresearch Corporate Summary
  • Company Overview
  • Products
• Sysmex Corporation
  • Table 8-123: Sysmex Corporate Summary
  • Company Overview
  • Products
  • Performance Review
    • Table 8-124: Sysmex Revenues, 2023-2024 (billion yen)
• TECHLAB, Inc.
  • Table 8-125: TECHLAB Corporate Summary
  • Company Overview
  • Products
• Teco Diagnostics
  • Table 8-126: Teco Diagnostics Corporate Summary
  • Company Overview
  • Products
• Thermo Fisher Scientific, Inc
  • Table 8-127: Thermo Fisher Scientific Corporate Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-128: Thermo Fisher Scientific Revenues, 2023-2024 ($ million)
• Tosoh Bioscience, Inc.
  • Table 8-129: Tosoh Bioscience Corporate Summary
  • Company Overview
  • Products
  • Company Financials
    • Table 8-130: Tosoh Corporation Revenue, 2023-2024 (billion yen)
• Trinity Biotech PLC
  • Table 8-131: Trinity Biotech Corporate Summary
  • Company Overview
  • Products
• True Diagnostics
  • Table 8-132: True Diagnostics Corporate Summary
  • Company Overview
  • Products
• VedaLab
  • Table 8-133: VedaLab Corporate Summary
  • Company Overview
  • Products
• Vircell
  • Table 8-134: Vircell Corporate Summary
  • Company Overview
  • Products
• WAMA Diagnostica
  • Table 8-135: WAMA Diagnostica Corporate Summary
  • Company Overview
  • Products
• Werfen Group
  • Table 8-136: Werfen Group Corporate Summary
  • Company Overview
  • Products
• Zeus Scientific, Inc.
  • Table 8-137: Zeus Scientific Corporate Summary
  • Company Overview
  • Products